SGP

SpyGlass Pharma, Inc.

Nasdaq · Surgical & Medical Instruments & Apparatus · Inc. DE · CIK 0001778922
$18.44 +1.93% $616.5M
Insider Buying Cluster (15 insiders)
Vol
Market Cap$616.5M
Cap SizeSmall Cap
Inst. Holders20 funds
Inst. Value$240.7M
Inst. Activity1 buys / 0 sells
Insider Activity9B / 0S
Insider Net $$162.7M
SEC Reports3
Press Releases2
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001778922·Prev Close $18.09

Recent Activity

May 24, 2026 SEC
HC Wainwright Initiates SGP at Buy — PT $37 (+52%)
ANALYST-UPGRADE — Impact 2/10
May 14, 2026 SEC
SpyGlass Pharma reported Q1 2026 net loss of $13.8M ($-0.69/share), in line with the $-0.67 consensus estimate. The comp
8-K — Impact 4/10
May 14, 2026 earnings
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
<p>ALISO VIEJO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“Spy
Apr 16, 2026 SEC
HC Wainwright initiates SGP with Buy — PT $37 (+46%) amid analyst cluster
ANALYST-UPGRADE — Impact 1/10
Mar 26, 2026 Press
SpyGlass Pharma reported its Q4 and full-year 2025 financial results alongside key clinical and corporate updates, inclu
Impact 8/10
Mar 9, 2026 Press
SpyGlass Pharma announced positive 12-month results from its Phase 1/2 trial of the BIM-IOL System, showing sustained in
Impact 8/10
Feb 9, 2026 Insider
Vensana Capital I GP, LLC disposed of 2,059,573 shares
10%+ Owner
Feb 9, 2026 Insider
Vensana Capital I GP, LLC disposed of 3,142,015 shares
10%+ Owner

Price Targets

Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$45.00 (Mar 2026)
Current $18.44 Low $37.00 Median $42.00 High $62.00 5 analysts
$37.00 $62.00

Analyst Ratings

Historical distribution89% buy · 9 analysts · last covering-analyst action Mar 2026
5Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
DateFirmActionRating
Mar 10, 2026 HC Wainwright & Co. INITIATE Buy
Mar 3, 2026 Citigroup INITIATE Buy
Mar 3, 2026 Leerink Partners INITIATE Outperform
Mar 3, 2026 Jefferies INITIATE Buy
Mar 3, 2026 Stifel INITIATE Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.55 ▼ -40.3% $-0.70 — $-0.44 3
Next Q $-0.58 ▼ -40.4% $-0.74 — $-0.50 3
Current FY $-2.31 ▼ -40.6% $-2.90 — $-1.92 -18% YoY 3
Next FY $-2.70 ▼ -40.6% $-3.89 — $-1.80 -17% YoY 3

Latest Reports

BULLISH ANALYST-UPGRADE 2/10
HC Wainwright Initiates SGP at Buy — PT $37 (+52%)
May 24, 2026
BULLISH ANALYST-UPGRADE 1/10
HC Wainwright initiates SGP with Buy — PT $37 (+46%) amid analyst cluster
Apr 16, 2026
BULLISH Press 8/10
SpyGlass Pharma reported its Q4 and full-year 2025 financial results alongside key clinical and corporate updates, inclu
Mar 26, 2026

Top Institutional Holders

FundValueMove
RA CAPITAL MANAGEMENT, L.P.$207.8MNEW
VANGUARD CAPITAL MANAGEMENT LLC$11.3M—
FRANKLIN RESOURCES INC$7.8M—
BlackRock, Inc.$3.8M—
VANGUARD FIDUCIARY TRUST CO$1.5M—

Recent Insider Trades

DateInsiderTypeValue
Feb 9, 2026Vensana CapitalC$0.00
Feb 9, 2026Vensana CapitalC$0.00
Feb 9, 2026Vensana CapitalC$0.00
Feb 9, 2026Vensana CapitalC$0.00
Feb 9, 2026Vensana CapitalBUY$2.6M
20 institutional holders with $240.7M total value (9,992,340 shares) as of 2026-Q1. Top holders: RA, VANGUARD, FRANKLIN. Net buying activity: 1 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1RA CAPITAL MANAGEMENT, L.P.8,021,117$207.8M86.4%NEW
2VANGUARD CAPITAL MANAGEMENT LLC434,813$11.3M4.7%—
3FRANKLIN RESOURCES INC300,000$7.8M3.2%—
4BlackRock, Inc.144,739$3.8M1.6%—
5VANGUARD FIDUCIARY TRUST CO59,782$1.5M0.6%—
6CHARLES SCHWAB INVESTMENT MANAGEMENT INC59,610$1.5M0.6%—
7Alyeska Investment Group, L.P.57,000$1.5M0.6%—
8TD ASSET MANAGEMENT INC47,580$1.2M0.5%—
9AMERIPRISE FINANCIAL INC44,477$1.2M0.5%—
10MARSHALL WACE, LLP29,348$760.4K0.3%—
11BANK OF AMERICA CORP /DE/28,020$726.0K0.3%—
12GOLDMAN SACHS GROUP INC19,283$499.6K0.2%—
13STATE STREET CORP17,250$446.9K0.2%—
14MANUFACTURERS LIFE INSURANCE COMPANY, THE11,870$307.6K0.1%—
15Vanguard Global Advisers, LLC4,927$127.7K0.1%—
16MORGAN STANLEY4,179$108.3K0.0%—
17VANGUARD PORTFOLIO MANAGEMENT LLC3,680$95.3K0.0%—
18PRICE T ROWE ASSOCIATES INC /MD/704,440$18.3K0.0%—
19BARCLAYS PLC140$3.6K0.0%—
20ROYAL BANK OF CANADA85$2.0K0.0%—

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
RA CAPITAL MANAGEMENT, L.P.NEW—8,021,117—$207.8M2026-Q1
9 unique insiders with 50 transactions. Net insider value: $162.7M ($162.7M bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Feb 9, 2026Vensana Capital I GP, LLC10%+ OwnerCONVERT2,059,573——
Feb 9, 2026Vensana Capital I GP, LLC10%+ OwnerCONVERT3,142,015——
Feb 9, 2026Vensana Capital I GP, LLC10%+ OwnerCONVERT3,142,015——
Feb 9, 2026Vensana Capital I GP, LLC10%+ OwnerCONVERT9,689,922——
Feb 9, 2026Vensana Capital I GP, LLC10%+ OwnerBUY165,000$16.00$2.6M
Feb 9, 2026Vensana Capital I GP, LLC10%+ OwnerCONVERT1,690,230——
Feb 9, 2026RA CAPITAL MANAGEMENT, L.P.DirectorCONVERT2,524,473——
Feb 9, 2026RA CAPITAL MANAGEMENT, L.P.DirectorBUY3,441,966$16.00$55.1M
Feb 9, 2026RA CAPITAL MANAGEMENT, L.P.DirectorCONVERT1,150,941——
Feb 9, 2026RA CAPITAL MANAGEMENT, L.P.DirectorCONVERT1,150,941——
Feb 9, 2026RA CAPITAL MANAGEMENT, L.P.DirectorCONVERT222,591——
Feb 9, 2026New Enterprise Associates 17, L.P.10%+ OwnerCONVERT1,619,240——
Feb 9, 2026New Enterprise Associates 17, L.P.10%+ OwnerBUY937,500$16.00$15.0M
Feb 9, 2026New Enterprise Associates 17, L.P.10%+ OwnerCONVERT1,619,240——
Feb 9, 2026New Enterprise Associates 17, L.P.10%+ OwnerCONVERT1,370,168——
Feb 9, 2026New Enterprise Associates 17, L.P.10%+ OwnerCONVERT1,370,168——
Feb 9, 2026New Enterprise Associates 17, L.P.10%+ OwnerCONVERT737,962——
Feb 9, 2026Florence Anthony A. Jr.10%+ OwnerCONVERT1,619,240——
Feb 9, 2026Florence Anthony A. Jr.10%+ OwnerBUY937,500$16.00$15.0M
Feb 9, 2026Florence Anthony A. Jr.10%+ OwnerCONVERT1,619,240——
Feb 9, 2026Florence Anthony A. Jr.10%+ OwnerCONVERT1,370,168——
Feb 9, 2026Florence Anthony A. Jr.10%+ OwnerCONVERT1,370,168——
Feb 9, 2026Florence Anthony A. Jr.10%+ OwnerCONVERT737,962——
Feb 9, 2026Florence Anthony A. Jr.10%+ OwnerCONVERT954,990——
Feb 9, 2026Makhzoumi Mohamad10%+ OwnerCONVERT1,619,240——
Feb 9, 2026Makhzoumi Mohamad10%+ OwnerBUY937,500$16.00$15.0M
Feb 9, 2026Makhzoumi Mohamad10%+ OwnerCONVERT1,619,240——
Feb 9, 2026Makhzoumi Mohamad10%+ OwnerCONVERT1,370,168——
Feb 9, 2026Makhzoumi Mohamad10%+ OwnerCONVERT1,370,168——
Feb 9, 2026Makhzoumi Mohamad10%+ OwnerCONVERT737,962——
Feb 9, 2026Makhzoumi Mohamad10%+ OwnerCONVERT954,990——
Feb 9, 2026Walker Paul Edward10%+ OwnerCONVERT1,619,240——
Feb 9, 2026Walker Paul Edward10%+ OwnerBUY937,500$16.00$15.0M
Feb 9, 2026Walker Paul Edward10%+ OwnerCONVERT1,619,240——
Feb 9, 2026Walker Paul Edward10%+ OwnerCONVERT1,370,168——
Feb 9, 2026Walker Paul Edward10%+ OwnerCONVERT1,370,168——
Feb 9, 2026Walker Paul Edward10%+ OwnerCONVERT737,962——
Feb 9, 2026Walker Paul Edward10%+ OwnerCONVERT954,990——
Feb 9, 2026Behbahani AliDirectorCONVERT1,619,240——
Feb 9, 2026Behbahani AliDirectorBUY937,500$16.00$15.0M
Feb 9, 2026Behbahani AliDirectorCONVERT1,619,240——
Feb 9, 2026Behbahani AliDirectorCONVERT1,370,168——
Feb 9, 2026Behbahani AliDirectorCONVERT1,370,168——
Feb 9, 2026Behbahani AliDirectorCONVERT737,962——
Feb 9, 2026Behbahani AliDirectorCONVERT954,990——
Feb 9, 2026SANDELL SCOTT D10%+ OwnerCONVERT1,619,240——
Feb 9, 2026SANDELL SCOTT D10%+ OwnerBUY937,500$16.00$15.0M
Feb 9, 2026SANDELL SCOTT D10%+ OwnerCONVERT1,619,240——
Feb 9, 2026SANDELL SCOTT D10%+ OwnerCONVERT1,370,168——
Feb 9, 2026Yang Rick10%+ OwnerBUY937,500$16.00$15.0M
3 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 2.3/10.
BULLISH ANALYST-UPGRADE 1/10
HC Wainwright initiates SGP with Buy — PT $37 (+46%) amid analyst cluster
Apr 16, 2026
BULLISH ANALYST-UPGRADE 2/10
HC Wainwright Initiates SGP at Buy — PT $37 (+52%)
May 24, 2026
NEUTRAL 8-K 4/10
SpyGlass Pharma reported Q1 2026 net loss of $13.8M ($-0.69/share), in line with the $-0.67 consensu
May 14, 2026
BULLISH 8/10
SpyGlass Pharma reported its Q4 and full-year 2025 financial results alongside key clinical and corp
Mar 26, 2026
BULLISH 8/10
SpyGlass Pharma announced positive 12-month results from its Phase 1/2 trial of the BIM-IOL System,
Mar 9, 2026
Historical analyst distribution (last covering-analyst action Mar 2026): 89% buy across 9 analysts — 5 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.

Analyst Price Targets

Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$45.00 mean target (Mar 2026)
$37.00 Low $62.00 High
MetricValue
Current Price$18.44
Target Low$37.00
Target Mean$45.00
Target Median$42.00
Target High$62.00
# Analysts5
Recommendation— (no recent coverage)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.55 $-0.70 $-0.44 — -40.3% — $0.0B — 3
Next Q
2026-09-30
 $-0.58 $-0.74 $-0.50 — -40.4% — $0.0B — 3
Current FY
2026-12-31
 $-2.31 $-2.90 $-1.92 -18.0% -40.6% 1↑ 1↓ $0.0B 0.0% 3
Next FY
2027-12-31
 $-2.70 $-3.89 $-1.80 -16.6% -40.6% 0↑ 2↓ $0.0B 0.0% 3

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.547
7d ago$-0.390-0.157
30d ago$-0.390-0.157
60d ago$-0.327-0.220
90d ago$0.000-0.547
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 5 initiations.

Historical Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Mar 10, 2026 HC Wainwright & Co. INITIATE — Buy
Mar 3, 2026 Citigroup INITIATE — Buy
Mar 3, 2026 Leerink Partners INITIATE — Outperform
Mar 3, 2026 Jefferies INITIATE — Buy
Mar 3, 2026 Stifel INITIATE — Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20265310089%
May 1, 20265310089%
Apr 1, 20265310089%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 14, 2026
earnings
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
<p>ALISO VIEJO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharm
Mar 30, 2026
short_interest
FTD: SGP — 48,293 shares ($1.1M) failed to deliver
Settlement: 20260330, Price: $22.61, FTD Value: $1,091,904.73, SPYGLASS PHARMA INC COM
Mar 27, 2026
short_interest
FTD: SGP — 52,246 shares ($1.3M) failed to deliver
Settlement: 20260327, Price: $25.20, FTD Value: $1,316,599.2, SPYGLASS PHARMA INC COM
Mar 26, 2026
earnings
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
<p>ALISO VIEJO, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopha
Mar 25, 2026
short_interest
FTD: SGP — 27,116 shares ($0.6M) failed to deliver
Settlement: 20260325, Price: $23.74, FTD Value: $643,733.84, SPYGLASS PHARMA INC COM
Mar 23, 2026
short_interest
FTD: SGP — 21,715 shares ($0.6M) failed to deliver
Settlement: 20260323, Price: $26.00, FTD Value: $564,590, SPYGLASS PHARMA INC COM
Mar 9, 2026
fda
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
<p>ALISO VIEJO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical com